IPCALAB · Ipca Laboratories Ltd · Biotechnology & Drugs
Last close, 30 Oct
5.4% below 52-week high
52-week range: as of 30 Oct 2026.
Weighted combination of 8 measured readings. Not a probability, a rating or a forecast.
Stock Condition as of 30 Oct 2026 close
Slowest input: promoter pledge (disclosed quarterly), as of 18 Jul 2026
Chart
Fundamentals as of 15 Sep 2026 · the company's own latest record is 47 days old
Revenue (latest Q)
₹2,788 Cr
Revenue YoY
PAT YoY
+72.3%
Operating margin
Revenue, last 8 quarters
P/E (TTM)
P/B
6.3
P/S (TTM)
4.9
Sector P/E
36.3
Dividend yield
+0.3%
| Company | P/E | P/B | Net margin | ROE | D/E | Div. yield |
|---|---|---|---|---|---|---|
| IPCALAB (this stock) | 33 | 6.3 | +12.9% | +16.2% | 0.1 | +0.3% |
| Sun Pharmaceutical Industries | 38.4 | 5.6 | +19.1% | +14.2% | 0.47 | +0.8% |
| Divi's Laboratories | 59.7 | 14.5 | +26.1% | +17.4% | 0 | +0.3% |
| Torrent Pharmaceuticals | 72.7 | 19.2 | +15.3% | +27.1% | 141.16 | +0.8% |
Promoter
stable
FII
rising 1q
MF
31.15% (-0.09pp)
falling 1q
Insider trades
| Date | Insider | Type | Qty | Value |
|---|---|---|---|---|
| 16 Feb 2026 | MANISH KUMAR JAIN | SELL | 3,000 | ₹44.47 lakh |
Bulk/block deals
No bulk/block deals in the last 12 months.
News timeline
- loweconomictimes.indiatimes.com· 26 Oct 2026, 09:25 amTech picks: Anand Rathi, Cyient among 5 stocks to buy for up to 18% returns in short term - Taking stock
- loweconomictimes.indiatimes.com· 26 Oct 2026, 08:33 amIpca Laboratories among 4 stocks showing RSI trending up - Trend watch
- lowthehindubusinessline.com· 24 Oct 2026, 09:53 pmBandu’s Blockbusters for October 25, 2026
- loweconomictimes.indiatimes.com· 18 Aug 2026, 08:44 amIpca Laboratories among 4 stocks showing bullish RSI upswing - Trend Watch
- loweconomictimes.indiatimes.com· 17 Aug 2026, 05:09 pmKEI Industries among 4 midcap stocks to hit 52-week highs & surge up to 15% in a month - New Peaks
Concalls & investor presentations
AI-generatedKey takeaway: During the earnings call held on August 14, 2026, management reported that Ipca Laboratories' domestic formulation business grew by 13% to approximately INR 1,082 crores in Q1 FY27, compared to INR 961 crores in Q1 FY26. The overall export business saw a growth of 34%, reaching around INR 603 crores. Management highlighted that the company's consolidated revenue increased by 21% to INR 2,788 crores. Despite challenges such as material price fluctuations and shipping delays, consolidated EBITDA margins improved to 22.88% from 18.39% year-on-year. Management noted that the chronic segment grew by 17.2%, while the acute segment grew by 8.9%. They also discussed the performance of their institutional and generic businesses, with significant growth reported in the institutional generic segment. Management set a goal of 14% to 16% growth for the current financial year, up from the previous guidance of 12% to 13%.
Management emphasized strong growth across various segments and improved profitability.
Sourced from an exchange-filed transcript, dated 17 Aug 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: Management reported that Ipca Laboratories' domestic business achieved a growth of approximately 12% in Q3 FY26, outperforming the Indian Pharmaceutical Market (IPM) growth of around 8.9%. The company maintained a market share of about 2.08% as of December 2025. The export formulation business grew by around 17% in Q3, while the API business remained flat. Consolidated revenue for Q3 was reported at INR 2,245 crores, reflecting a growth of 6.5% year-on-year. The stand-alone EBITDA margin improved to 26.09%, and the consolidated EBITDA margin reached 22.5%. Management discussed challenges faced by Unichem, including market share loss in the U.S. and plans for recovery through new product launches. They also highlighted growth in various segments, including pain and cardiovascular, while noting a decline in antimalarial sales. Overall, management expressed confidence in continuing to outperform the market.
The tone reflected both positive growth in certain segments and challenges in others.
Sourced from an exchange-filed transcript, dated 18 Feb 2026. Summary is RedixFi-generated and distinct from investment advice.
AI Summary of Annual Report
AI-generatedIPCA Laboratories Limited (IPCALAB) reported FY2025-26 results with no material changes affecting its financial position post-year-end. The company reappointed Prashant Godha as Executive Director for five years, subject to shareholder approval. Credit ratings remain stable with IND AA+ for long-term loans and working capital. The company faces pending tax disputes, including ₹4.15 crores in disputed excise penalties from Tonira Pharma, secured by a ₹2.00 crores bank guarantee. No defaults on loans or statutory dues were reported, and internal controls were deemed adequate. The company maintains a strong workforce of 18,667 employees and continues to invest in R&D and infrastructure, with key projects in progress.
- No material changes or commitments affecting financial position post-FY2025-26 end.
- Prashant Godha reappointed as Executive Director for five years, pending shareholder approval.
- Credit ratings stable with IND AA+ for long-term loans and working capital.
- Pending tax disputes include ₹4.15 crores in disputed excise penalties secured by ₹2.00 crores bank guarantee.
- No defaults on loans or statutory dues reported; internal controls deemed adequate.
Key takeaway: IPCA Laboratories Limited maintains stable financial operations with no defaults, but faces pending tax disputes that could impact future financials.
The following annual report excerpts provide qualitative strategic context. Do not treat any specific financial figures in these excerpts as authoritative — they may be incorrectly labeled due to PDF table extraction limitations. For precise financial data, refer to the structured fundamentals data above.
Governance disclosures
AI-generatedNeeds attention
No item of a kind that needs attention was stored for this company.
Contingent Liability
2 occurrencesRecent (last 12 months)
The company has a contingent liability of ₹2.00 crores for a bank guarantee provided to the excise department related to a dispute with Tonira Pharma Limited, which was amalgamated with the company. Additionally, there is a contingent liability of ₹11.00 crores from a term deposit with RBL Bank as security for an associate company's short-term credit facility.
Earlier (1-3 years ago)
The company has provided loans and made investments in related parties, including a subsidiary and an associate, with amounts and purposes disclosed in the notes to the standalone financial statements.
Related-Party Transaction
2 occurrencesRecent (last 12 months)
The company has disclosed related party transactions with entities in which directors or their relatives have significant influence, including Nipra Industries Pvt. Ltd., Vandhara Industries Pvt. Ltd., Prabhat Foundation, Vandhara Resorts Pvt. Ltd., and Ipca Foundation, as detailed in Statement 1 of the financial statements.
Earlier (1-3 years ago)
The company has related party transactions with entities such as Nipra Industries Pvt. Ltd., Nipra Packaging Pvt. Ltd., Prabhat Foundation, Vandhara Resorts Pvt. Ltd., Resonance Specialties Limited, and Ipca Foundation. These transactions are detailed in Statement 1 attached to the financial statement.
Statutory dues in dispute
2 occurrencesRecent (last 12 months)
The company has disputes over statutory dues including Excise Duty, Service Tax, Sales Tax, and GST with various authorities, involving amounts and pending in multiple forums.
Earlier (1-3 years ago)
The company has outstanding statutory dues for Excise Duty (2019-20, 2001-02), Service Tax (2017, 2006-07, 2012-13), and Sales Tax (2006-07) with specified authorities, involving amounts and pending disputes.
Promoter Share Pledge
1 occurrenceRecent (last 12 months)
0.49% of promoter holding pledged (quarter 2026-Q3 as of 2026-07-18).